Reinventing Arena to focus on Phase II clinical candidates

January 31, 2017 Christoph Graener

In the six months after joining Arena Pharmaceuticals as CEO, Dr. Amit Munshi has been busy: reducing the company’s commitment to obesity drug Belviq, which it has partnered with Eisai; spinning out the discovery research activities into a new company, Beacon Discovery; and prioritizing three Phase II programs with readouts in 2017. Munshi updates Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, on the company’s progress to date.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Amit Munshi – CEO, Arena Pharmaceuticals

Previous Article
J&J poised to establish no-strings-attached JLABS outside America

As J&J announced the establishment of its eighth JLABS facility, Melinda Richter, head of J&J Innovation, J...

Next Article
ProNAI defects from oligos to DDR as Sierra Oncology

Sierra Oncology president and CEO Dr. Nick Glover explains how the company is rebranding itself from its fo...